Now Playing
Opinion|Videos|September 30, 2024
Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making
Author(s)Rana R. McKay, MD
Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly diagnosed patients.
Advertisement
Episodes in this series
- How has the first-line treatment landscape for metastatic renal cell carcinoma (mRCC) evolved in recent years?
- What factors influence your decision for newly diagnosed mRCC patients?
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5